Pharmaceutical Substances - Version 4.9
The version 4.9 of Pharmaceutical Substances was launched in December 2020.
Pharmaceutical Substances 4.9 contains 13 new APIs and a total of 44.235 structures, 12.673 reactions, and 2.763 active pharmaceutical ingredients.
Statement by the authors Prof. Axel Kleemann, Prof. Bernhard Kutscher and Dr. Dietmar Reichert
"This release is focused on 13 new active pharmaceutical ingredients (APIs) as well as one update and includes many drug products that have an innovative mechanism of action as well as FDA breakthrough status.
Among them are the kinase inhibitors Capmatinib, Pemigatinib, Ripretinib, Selpercatinib, Selumetinib and Tucatinib all approved as specific anticancer drugs.
Recent international approval was also received by Bempedoic acid for treatment of hypercholesterolemia and the immunomodulatory drug Ozanimod for treatment of relapsing Multiple Sclerosis (MS).
Additionally, you will find new entries such Amifampridine for treatment of a rare muscle disease, the tuberculostatic agent Bedaquilline, and also Naloxegol, Prucalopride and Valbenazine in this release."
Thieme Chemistry Marketing Phone:+49-711-89310 E-Mail